Many COVID-19 patients are participating in trials and studies evaluating whether heart and anti-platelet drugs are effective treatments, according to The Wall Street Journal.
Some researchers argue that COVID-19 is a vascular disease as well as a respiratory one and have been testing cardiovascular drugs' ability to reduce inflammation and fluid in the lungs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,